Kiovig (Human Normal Immunoglobulin)

Human normal immunoglobulin supplies a broad range of IgG antibodies that can bind to pathogens, neutralize toxins, and opsonize microbes for clearance. It also interacts with immune cells via Fc receptors, modulating cytokine production and reducing auto‑antibody formation, thereby restoring immune balance and providing passive protection.

The dose of Kiovig is individualized by the prescribing clinician based on the patient’s weight, indication, and clinical response. Healthcare providers calculate the appropriate infusion volume and rate according to established guidelines and monitor the patient throughout the administration.

The safety of Kiovig in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order Kiovig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics—and necessary import documentation.

Kiovig is a high‑purity, solvent‑detergent‑treated IVIG product comparable to other branded IVIGs in terms of IgG content and safety profile. Differences may exist in stabilizers, infusion rates, and manufacturing processes, but clinical efficacy for approved indications is generally similar across products.

Kiovig must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Do not use if the solution appears discolored or contains particles.

Kiovig is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate is started slowly and may be increased as tolerated, with vital signs monitored throughout the procedure to detect any adverse reactions.

Serious risks include anaphylactic reactions, thromboembolic events, acute renal failure, hemolysis, aseptic meningitis, and transfusion‑related acute lung injury (TRALI). Patients should be closely monitored during and after infusion for any signs of these complications.

Kiovig is contraindicated in patients with a known severe IgA deficiency who have experienced anaphylaxis to blood products, and in those with a history of severe allergic reactions to immunoglobulin therapy. It should also be avoided in patients with uncontrolled hyperviscosity or active thrombotic disease.